机构：[1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China[2]Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China[3]The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China河南省肿瘤医院[4]Gansu Provincial Cancer Hospital, Lanzhou, China[5]Gansu Cancer Hospital, Lanzhou, China[6]Linyi People's Hospital, Linyi, China[7]Beijing Cancer Hospital, Beijing, China[8]Peking University People's Hospital, Beijing, China[9]Department of Oncology, Peking Union Medical College Hospital, Beijing, China[10]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[11]Department of Radiation Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China[12]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China[13]Shenyang Chest Hospital, Shenyang, China[14]Akeso Biopharma, Inc., Zhongshan, China[15]Department of Clinical Medicine, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China
Zhang Changgong,Yang Sheng,Chen Jianhua,et al.Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy.[J].JOURNAL OF CLINICAL ONCOLOGY.2021,39(15):doi:10.1200/JCO.2021.39.15_suppl.8568.
APA：
Zhang, Changgong,Yang, Sheng,Chen, Jianhua,Wu, Huijuan,Wang, Jun...&Shi, Yuankai.(2021).Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy..JOURNAL OF CLINICAL ONCOLOGY,39,(15)
MLA：
Zhang, Changgong,et al."Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy.".JOURNAL OF CLINICAL ONCOLOGY 39..15(2021)
医学